Baker Bros. Advisors ROIV Position
Active9-Fund ConvergenceBaker Bros. Advisors increased their position in Roivant Sciences Ltd. (ROIV) in Q4 2025, holding $120.5M worth of shares across 5,555,017 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ROIV is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Full company profile →Short Interest
4.3%
4.1 days to cover
Baker Bros. Advisors ROIV Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 5,555,017 | +1,787,244 | $120.5M |
| Q3 2025 | Held | 3,767,773 | — | $57.0M |
| Q2 2025 | Held | 3,767,773 | — | $42.5M |
| Q1 2025 | Held | 3,767,773 | — | $38.0M |
| Q4 2024 | Increased | 3,767,773 | +969,057 | $44.6M |
| Q3 2024 | Held | 2,798,716 | — | $32.3M |
| Q2 2024 | Decreased | 2,798,716 | -4,615,118 | $29.6M |
| Q1 2024 | Decreased | 7,413,834 | -179,190 | $78.1M |
| Q4 2023 | Decreased | 7,593,024 | -4,284,147 | $85.3M |
| Q3 2023 | Increased | 11,877,171 | +2,448,579 | $138.7M |
| Q2 2023 | Increased | 9,428,592 | +4,651,162 | $95.0M |
| Q1 2023 | New | 4,777,430 | +4,777,430 | $35.3M |
Frequently Asked Questions
Does Baker Bros. Advisors own ROIV?
Yes. As of Q4 2025, Baker Bros. Advisors holds 5,555,017 shares of Roivant Sciences Ltd. (ROIV) valued at $120.5M. This data comes from their SEC 13F filing.
How many hedge funds own ROIV?
9 specialist biotech hedge funds currently hold ROIV, including Perceptive Advisors, Avoro Capital Advisors, OrbiMed Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy ROIV?
Baker Bros. Advisors's position in ROIV was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's ROIV position increasing or decreasing?
Baker Bros. Advisors increased their ROIV position in the most recent quarter, adding 1,787,244 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ROIVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →